|Bid||8,681.00 x 0|
|Ask||8,683.00 x 0|
|Day's range||8,507.00 - 8,710.00|
|52-week range||6,499.80 - 8,848.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||40.08|
|Forward dividend & yield||2.02 (2.37%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
The company's next-generation treatment for breast cancer could become the new standard of care.